Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00114023 · ClinicalTrials.gov registry record
1-Year Follow up to the 1473-IMIQ Study
A clinical trial of Keratosis, sponsored by Graceway Pharmaceuticals.
- Completed
- Registry status
- 84
- Enrollment target
- 1
- Study location
NCT00114023 is a study of Keratosis that has completed, run by Graceway Pharmaceuticals. The registered enrollment target is 84 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00114023, a study of Keratosis, has completed, sponsored by Graceway Pharmaceuticals.
- COMPLETED
- Registry status
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 1-year follow-up study to evaluate the long-term effects in subjects who completely cleared their actinic keratosis (AK) lesions in the 1473-IMIQ study. The 1473-IMIQ study evaluated the safety and effectiveness of imiquimod 5% cream compared to a placebo cream for the treatment of AK.
Conditions Studied
Interventions
- DRUG Imiquimod 5% cream
Study Locations (1)
Arkansas
- - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2005-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00114023
The ClinicalTrials.gov registry entry for NCT00114023 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Graceway Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Keratosis appearing as the primary indexed condition, and to 1 intervention - of which Imiquimod 5% cream is the first listed.
NCT00114023 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT00114023 about?
NCT00114023 is a clinical study titled "1-Year Follow up to the 1473-IMIQ Study". This is a 1-year follow-up study to evaluate the long-term effects in subjects who completely cleared their actinic keratosis (AK) lesions in the 1473-IMIQ study. The 1473-IMIQ study evaluated the safety and effectiveness of imiquimod 5% cream compared to a placebo cream for the treatment of AK.
What is the current status of trial NCT00114023?
This trial is currently completed. The enrollment target is 84 participants. The study started on 2005-01.
What conditions does trial NCT00114023 study?
This clinical trial studies the following conditions: Keratosis.
What interventions are being tested in trial NCT00114023?
The interventions under investigation include: Imiquimod 5% cream (DRUG).
Who is sponsoring clinical trial NCT00114023?
This trial is sponsored by Graceway Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00114023 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.